(Date:12/4/2009)...e/ -- Stemline Therapeutics, Inc. today announced ...argeting agents, SL-401 and SL-501, in both in vi...ukemia (CML) have been selected for poster present...merican Society of Hematology (ASH), to be held in...ill be presented by Stemline,s collaborators at Th...
(Date:12/3/2009)...wire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasd...e development of compounds for the treatment of ca...d that it has completed the last patient visit in ..., The FDG-PET trial enrolled 52 patients and wa...ncluding Massachusetts General Hospital, Mount Sin...
(Date:12/3/2009)...Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D.,...otechnology Co. Ltd.,( http://www.beikebiotech.com...oot Care in New Delhi, India, November 22, 2009. B...enerative medicine company. , The confere...(IPA), aimed,to help podiatrists and researchers w...
(Date:12/2/2009)...wire/ -- Reportlinker.com announces that a new mar... ,, Drug Discovery Technologies - A Global Upd...ttp://www.reportlinker.com/p0164246/Drug-Discovery...Opportunities.html ,, Drug discovery has becom...eutical company,s business strategy. There are a n...
Breaking Biology Technology:Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9...s market average selling price for dental implants...r European countries, WALTHAM, Mass., Nov. 19 Mi...Marketrack service offers insight into an importan...age price of dental,implants sold in Italy is near...ermany, France, and the UK. The presence of many m...
...Md., Nov. 16 Spherix Incorporated,(Nasdaq: SPEX ...f $3.1,million ($0.22 per share) and $7.1 million ...ended September 30, 2007, respectively. These loss...ds of 2006 due to increased,expenditures related t...e,as a treatment for type 2 diabetes. The Company ...
...lease is available in German . , Many scientists...mple methods for the production of tiny particles ...special regular patterns in two or three dimension...miniature objects have countless applications in m...eneration of artificial tissues to improved data s...
Other Biology Technology:Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market 2Spherix Reports 3rd Quarter Earnings 2Two-faced miniatures 2Anti-alpha1-Antitrypsin Monoclonal Antibody, Unconjugated from CHEMICON
Mouse LIGHT / TNFSF14, Unconjugated from R&D Systems
Ral Immunoblot Assay Kit from Upstate
BL21 Star (DE3) One Shot Chemically Competent E. coli from Invitrogen
Biology Products: